Table 3.

Antiapoptotic effects of IRX-2 in comparison to IL-2, IL-7 and IL-15 in MV- or CH-11 Ab-induced^a primary T cells^a

	CD8+ cells		CD4+ cells
	FITC-VAD-FMK+ cells	P-valueb	FITC-VAD-FMK+ cells	P-valueb
(A) MV-induced apoptosis
Control	21.8±3.9	—	14.3±5.0	—
No IRX-2+MV	71.0±8.0	—	45.7±1.6	0.0222c
+IRX-2+MV	20.6±0.8	0.0006	10.2±0.4	0.0038
+IL-7+MV	49.5±3.5	0.0004	34.5±1.9	0.0124
+IL-15+MV	16.8±6.2	0.0044	16.7±2.1	0.0072
+IL-7/IL-15+MV	11.8±6.2	0.0036	11.9±0.8	0.0031
+IL-2+MV	21.9±2.7	0.0002	22.2±2.7	0.0113
(B) CH-11 Ab-induced apoptosis
Control	12.3±2.8	—	11.4±1.3	—
No IRX-2+MV	50.0±0.2	—	46.8±3.0	—
+IRX-2+MV	13.4±3.0	0.0007	12.0±1.7	0.0001
+IL-7+MV	37.7±1.4	0.0015	31.8±10.6	—
+IL-15+MV	28.8±3.1	0.0020	21.1±5.3	0.0086
+IL-7/IL-15+MV	24.2±4.9	0.0028	20.2±0.1	0.0010
+IL-2+MV	44.2±6.9	—	31.7±3.0	0.0128

^aActivated primary CD8⁺ and CD4⁺ T cells were preincubated with IRX-2 (1 : 3 dilution), recombinant human IL-2 (100 IU/ml), IL-7 (10 ng/ml), IL-15 (10 ng/ml) or IL-7 and IL-15 (both 10 ng/ml) for 24 h and then treated with 10 μg MV or 400 ng/ml CH-11 Ab for an additional 24 h. Activation of caspases was analyzed by flow cytometry. The data are mean percentages of FITC-VAD-FMK+ cells±S.D. obtained in three independent experiments.

^bThe P-values refer to significant differences between cells pretreated with IRX-2 compared to MV alone or cells pretreated with the indicated cytokine compared to those pretreated with IRX-2.

^cThe P-value refers to the difference in sensitivity to MV-mediated apoptosis between CD8⁺ and CD4⁺ T cells